Cargando…

Rheumatologists’ perspective on hydroxychloroquine guidelines

OBJECTIVE: Hydroxychloroquine (HCQ) retinal toxicity is an ongoing concern for rheumatologists. The revised 2016 American Academy of Ophthalmology (AAO) guidelines created controversy regarding the correct dosing and evaluation of HCQ toxicity. The current study was initiated to further understand r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winebrake, James, Khalili, Leila, Weiner, Julia, Gartshteyn, Yevgeniya, Park, Lisa, Askanase, Anca D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640534/ https://www.ncbi.nlm.nih.gov/pubmed/33148665 http://dx.doi.org/10.1136/lupus-2020-000427

Ejemplares similares

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data
por: Tang, Wei, et al.
Publicado: (2021)

Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus
por: Vázquez-Otero, Ileana, et al.
Publicado: (2020)

Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners
por: Arat, Seher, et al.
Publicado: (2017)

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety
por: Cornet, Alain, et al.
Publicado: (2021)

Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments
por: Askanase, Anca, et al.
Publicado: (2015)

The Impact of Telemedicine on Rheumatology Care
por: Tang, Wei, et al.
Publicado: (2022)

The Use of COVID-19 Vaccines in Patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2021)

Hydroxychloroquine Use Is Not Associated With QTc Length in a Large Cohort of SLE and RA Patients
por: Park, Elizabeth, et al.
Publicado: (2021)

Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients
por: Park, Elizabeth, et al.
Publicado: (2021)

Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development
por: Garg, Shivani, et al.
Publicado: (2022)

Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards
por: Garg, Shivani, et al.
Publicado: (2023)

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2020)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2021)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

COVID-19 and systemic lupus erythematosus: a case series
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2020)

Prevalence of coronary artery calcification in young patients with SLE of predominantly Hispanic and African–American descent
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2019)

Infection hospitalisation in systemic lupus in Sweden
por: Simard, Julia F, et al.
Publicado: (2021)

Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus
por: Zhu, Lisa, et al.
Publicado: (2022)

Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries
por: Lieber, Sarah B, et al.
Publicado: (2023)

SLAMF6 compartmentalization enhances T cell functions
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2022)

Factors associated with pain coping and catastrophising in patients with systemic lupus erythematosus: a cross-sectional study of the LuLa-cohort
por: Fischin, Julia, et al.
Publicado: (2015)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre
por: Anastasiou, Christine, et al.
Publicado: (2018)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
por: Schlencker, Aurelien, et al.
Publicado: (2022)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus
por: Kheir, Joseph M, et al.
Publicado: (2018)

Patients with overlap autoimmune disease differ from those with ‘pure’ disease
por: Lockshin, Michael D, et al.
Publicado: (2015)

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
por: Lokhandwala, Tasneem, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tpl0u6e2f1o7hp9lqc2iqhs53r